Pilot study of a myostatin antagonist in dogs with cardiac cachexia

Freeman, Lisa M.; Cunningham, Suzanne M.; Yang, Vicky; Bulmer, Barret J.

doi:10.1016/j.jvc.2015.06.004

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of promising studies in rodent models of cachexia have been completed [7], and several Phase 1 and 2 human clinical trials are underway to study the effects of myostatin inhibitors in muscular dystrophy, cancer, and kidney disease (www.clinicaltrials.gov). A small, open-label pilot study of a myostatin antagonist (activin receptor type IIB) was conducted in pet dogs with naturally-occurring CHF [94]. While no significant improvements occurred in body weight, there was a numerical, but not significant, increase in MCS.…”

Section: Myostatinmentioning

confidence: 99%

Cachexia and Sarcopenia in Companion Animals: An Under‐Utilized Natural Animal Model of Human Disease

Freeman

2018

JCSM Rapid Communications

Self Cite

View full text Add to dashboard Cite

While laboratory small animal models of cachexia and sarcopenia are well-suited and critical for studying mechanisms and early pre-clinical phases for potential treatments, they are not similar enough to the human conditions to always be good predictors for results in human clinical trials. As a result, translational failures can occur when large-scale human clinical trials are conducted on drugs, even when they appear promising in pre-clinical studies in rodent models. What is needed is a way to more efficiently and successfully translate information gained from basic science and rodent research into human clinical trials that produce effective approved drugs. Naturally-occurring cachexia and sarcopenia in companion animals is a more representative model of human disease that can serve as a stepping stone between basic science and human clinical trials. Many of the common diseases of humans also affect companion animals, particularly pet dogs and cats. Pet dogs and cats commonly develop heart failure, cancer, and kidney disease, as well as acute trauma or illness. The population of elderly companion animals also is increasing as pets' lifespans have become longer. As a result, both cachexia and sarcopenia are very common in companion animals. Studying these conditions in dogs and cats -either in colonies or in animal clinical trials -can help to identify successful treatments that can benefit both humans and companion animals.

show abstract

Section: Myostatinmentioning

confidence: 99%

Cachexia and Sarcopenia in Companion Animals: An Under‐Utilized Natural Animal Model of Human Disease

Freeman

2018

JCSM Rapid Communications

Self Cite

View full text Add to dashboard Cite

show abstract

“…The resultant increase in serum myostatin levels associated with the endocrine pathway can be measured and reduction of these levels is a potential target for prevention of disuse atrophy. The use of a canine-specific activin receptor type IIB decoy receptor in dogs did not reverse cardiac cachexia, but reduction of serum myostatin by an insertion of a canine myostatin propeptide gene utilizing an adeno-associated virus serotype 8 vector increased muscle mass in both healthy dogs and golden retrievers with muscular dystrophy [5][6][7].…”

Section: Introductionmentioning

confidence: 96%

Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Other studies evaluated the clinical findings and the survival time following the administration of the drugs [ 385 ], X-ray and ultrasound images after the treatment [ 386 ], and the “aldosterone breakthrough” following the administration of ACE inhibitors [ 387 ]. Furthermore, a study on a myostatin antagonist used to counteract cardiac cachexia secondary to CHF has also been published [ 388 ]. In recent years, the evaluation of NT-pro BNP levels following the cardiological treatment has gained a lot of interest; in fact, low levels of this molecule indicate a better prognosis [ 389 , 390 ].…”

Section: Resultsmentioning

confidence: 99%

Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020

Bagardi

Zamboni

Locatelli

et al. 2022

Animals

View full text Add to dashboard Cite

The treatment of chronic congestive heart failure (CHF), secondary to myxomatous mitral valve disease (MMVD) in dogs, has considerably changed in the last fifty years. An analysis of the literature concerning the therapy of chronic CHF in dogs affected by MMVD is not available, and it is needed. Narrative reviews (NRs) are aimed at identifying and summarizing what has been previously published, avoiding duplications, and seeking new study areas that have not yet been addressed. The most accessible open-access databases, PubMed, Embase, and Google Scholar, were chosen, and the searching time frame was set in five decades, from 1970 to 2020. The 384 selected studies were classified into categories depending on the aim of the study, the population target, the pathogenesis of MMVD (natural/induced), and the resulting CHF. Over the years, the types of studies have increased considerably in veterinary medicine. In particular, there have been 43 (24.29%) clinical trials, 41 (23.16%) randomized controlled trials, 10 (5.65%) cross-over trials, 40 (22.60%) reviews, 5 (2.82%) comparative studies, 17 (9.60%) case-control studies, 2 (1.13%) cohort studies, 2 (1.13%) experimental studies, 2 (1.13%) questionnaires, 6 (3.40%) case-reports, 7 (3.95%) retrospective studies, and 2 (1.13%) guidelines. The experimental studies on dogs with an induced form of the disease were less numerous (49–27.68%) than the studies on dogs affected by spontaneous MMVD (128–72.32%). The therapy of chronic CHF in dogs has considerably changed in the last fifty years: in the last century, some of the currently prescribed drugs did not exist yet, while others had different indications.

show abstract

Pilot study of a myostatin antagonist in dogs with cardiac cachexia

Cited by 6 publications

References 16 publications

Cachexia and Sarcopenia in Companion Animals: An Under‐Utilized Natural Animal Model of Human Disease

Cachexia and Sarcopenia in Companion Animals: An Under‐Utilized Natural Animal Model of Human Disease

Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy

Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020

Contact Info

Product

Resources

About